CYP1A1 is modestly or unexpressed in healthy tissues such as lungs [10], digestive tract [11], and normal breast tissues [12], fostering the design of prodrugs based on the oxidative activity of that enzyme to kill selectively BC cells. The gene discussed is CYP1A1; the disease is breast cancer.